Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquisition of certain Neurocords LLC's ("Neurocords") assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI). The global spinal cord injury treatment market size was valued at $7.5...
Read more








